ST. PAUL, Minn., Oct. 11, 2016/PRNewswire/ - EnteroMedics Inc. (NASDAQ: ETRM), the designer of therapeutic gadgets utilizing neuroblocking innovation to treat stoutness, metabolic sicknesses and other gastrointestinal issue, today highlighted the Company's late accomplishments in a letter to shareholders, in front of the Company's expected extraordinary meeting of shareholders to be held October 19, 2016.
Dear Shareholders:
As I consider my first year as Chief Executive Officer of EnteroMedics, I am satisfied with the advance we've made as an organization and now, like never before, trust we have stepped toward extending the accessibility of vBloc® Therapy to a vast and developing number of those living with a sickness which has turned out to be one of the best dangers to general wellbeing in current history: weight.
A week ago, on October 5, 2016, we declared maybe our most noteworthy triumph towards accomplishing this objective. Through a national contract with our circulation accomplice, Academy Medical, LLC, we declared that vBloc Therapy is presently accessible to all U.S. veterans at VA medicinal offices. This implies the more than one million hefty U.S. Veterans may get vBloc Therapy at any VA medicinal office at practically zero cost as per their Veterans' medical advantages.
It is a respect to have the capacity to give this progressive, successful choice to the extremely chubby men and ladies who have so valiantly and benevolently served our nation. We anticipate working intimately with the VA and Academy Medical to prepare VA specialists so they are set up to offer vBloc Therapy and start performing inserts as quickly as time permits. In parallel, our forceful endeavors to get expansive repayment scope for vBloc Therapy proceed, as we trust all patients merit access to each alternative that may help in their fight against stoutness.
Supporting this exertion, vBloc Therapy is upheld by a solid and broad collection of research, including as of late declared 24-month comes about because of our significant ReCharge Study, distributed this past August in Obesity Surgery. These outcomes affirm the solid way of the weight reduction accomplished with vBloc Therapy, and also the positive effect it had on patients' stoutness related comorbidities. As imperatively, in studies, vBloc Therapy has shown a much better wellbeing profile than other bariatric methodology, a variable that effects quiet personal satisfaction, as well as decreases the general cost of treatment by lessening the requirement for expensive mediation.
While this exploration additionally approves our trust in vBloc Therapy, maybe most moving is the developing number of direct patient examples of overcoming adversity we've had the benefit of finding out about and offering to you. Addressing patients whose lives have been definitely enhanced through this earth shattering treatment just reinforces our dedication to conveying vBloc Therapy to whatever number patients as could be expected under the circumstances.
EnteroMedics has booked a vital Special Meeting of Shareholders for Wednesday, October 19, 2016. In the event that you were a shareholder of record at the end of business on September 14, 2016, you are qualified for vote at the Special Meeting. Your intermediary support and vote is basic to accomplishing our objectives and assisting our prosperity.
As the president and CEO of EnteroMedics, as well as a kindred shareholder, I ask you to practice your entitlement to vote your shares. An update intermediary was sent out to unvoted shareholders a week ago. It would be ideal if you make incite move to vote your EnteroMedics offers, ideally by web or phone, by taking after the voting directions included with our intermediary materials.
In the event that you have not yet voted or lost your Proxy and need help with voting your shares, please contact The Proxy Advisory Group LLC, which is helping us, either by phone: 212-616-2180 or email: info@proxyadvisory.net.
We thank you for your intermediary support and anticipate offering our future victories to you.
Earnestly,
Dan W. Gladney
President and Chief Executive Officer
About EnteroMedics Inc.
EnteroMedics is a restorative gadget organization concentrated on the advancement and commercialization of its neuroscience based innovation to treat heftiness and metabolic illnesses. vBloc® Neurometabolic Therapy, conveyed by a pacemaker-like gadget called the vBloc® System, is intended to irregularly obstruct the vagus nerves utilizing high-recurrence, low-vitality, electrical motivations. EnteroMedics' vBloc® System has gotten U.S. Nourishment and Drug Administration endorsement and CE Mark.
Data about the vBloc® System and vBloc® Neurometabolic Therapy
You ought not have an embedded vBloc® System on the off chance that you have cirrhosis of the liver, hypertension in the veins of the liver, amplified veins in your throat or a critical hiatal hernia of the stomach; on the off chance that you require attractive reverberation imaging (MRI); in the event that you have a forever embedded, electrical medicinal gadget; or in the event that you require a diathermy method utilizing heat. The most widely recognized related antagonistic occasions that were experienced amid clinical investigation of the vBloc System included agony, acid reflux, sickness, trouble gulping, burping, wound redness or aggravation, and blockage.
Converse with your specialist about the full dangers and advantages of vBloc Therapy and vBloc System. For extra recommending data, please visit www.enteromedics.com.
On the off chance that you are keen on adapting more about vBloc Neurometabolic Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This official statement contains forward-looking proclamations about EnteroMedics Inc. Our genuine outcomes could vary tangibly from those talked about because of known and obscure dangers, instabilities and different elements including our constrained history of operations; our misfortunes since origin and for a long time to come; our restricted business deals involvement with our vBloc® System for the treatment of weight in the United States or in any outside market other than Australia and the European Community; our capacity to recover and afterward keep up consistence with the Nasdaq kept posting necessities; our capacity to popularize our vBloc® System; our reliance on outsiders to start and play out our clinical trials; the need to acquire administrative endorsement for any adjustments to our vBloc® System; doctor selection of our vBloc® System and vBloc® Neurometabolic Therapy; our capacity to get outsider coding, scope or installment levels; continuous administrative consistence; our reliance on outsider makers and providers; the fruitful improvement of our deals and showcasing capacities; our capacity to raise extra capital when required; universal commercialization and operation; our capacity to pull in and hold administration and other staff and to deal with our development successfully; potential item obligation claims; potential social insurance misrepresentation and manhandle claims; human services authoritative change; and our capacity to get and keep up licensed innovation security for our innovation and items. These and extra dangers and vulnerabilities are portrayed all the more completely in the Company's filings with the Securities and Exchange Commission, especially those variables distinguished as "hazard elements" in the yearly provide details regarding Form 10-K recorded March 28, 2016. We are giving this data as of the date of this official statement and don't attempt any commitment to upgrade any forward-looking proclamations contained in this report therefore of new data, future occasions or something else.
Logo - http://photos.prnewswire.com/prnh/20160502/362531LOGO
Dear Shareholders:
As I consider my first year as Chief Executive Officer of EnteroMedics, I am satisfied with the advance we've made as an organization and now, like never before, trust we have stepped toward extending the accessibility of vBloc® Therapy to a vast and developing number of those living with a sickness which has turned out to be one of the best dangers to general wellbeing in current history: weight.
A week ago, on October 5, 2016, we declared maybe our most noteworthy triumph towards accomplishing this objective. Through a national contract with our circulation accomplice, Academy Medical, LLC, we declared that vBloc Therapy is presently accessible to all U.S. veterans at VA medicinal offices. This implies the more than one million hefty U.S. Veterans may get vBloc Therapy at any VA medicinal office at practically zero cost as per their Veterans' medical advantages.
It is a respect to have the capacity to give this progressive, successful choice to the extremely chubby men and ladies who have so valiantly and benevolently served our nation. We anticipate working intimately with the VA and Academy Medical to prepare VA specialists so they are set up to offer vBloc Therapy and start performing inserts as quickly as time permits. In parallel, our forceful endeavors to get expansive repayment scope for vBloc Therapy proceed, as we trust all patients merit access to each alternative that may help in their fight against stoutness.
Supporting this exertion, vBloc Therapy is upheld by a solid and broad collection of research, including as of late declared 24-month comes about because of our significant ReCharge Study, distributed this past August in Obesity Surgery. These outcomes affirm the solid way of the weight reduction accomplished with vBloc Therapy, and also the positive effect it had on patients' stoutness related comorbidities. As imperatively, in studies, vBloc Therapy has shown a much better wellbeing profile than other bariatric methodology, a variable that effects quiet personal satisfaction, as well as decreases the general cost of treatment by lessening the requirement for expensive mediation.
While this exploration additionally approves our trust in vBloc Therapy, maybe most moving is the developing number of direct patient examples of overcoming adversity we've had the benefit of finding out about and offering to you. Addressing patients whose lives have been definitely enhanced through this earth shattering treatment just reinforces our dedication to conveying vBloc Therapy to whatever number patients as could be expected under the circumstances.
EnteroMedics has booked a vital Special Meeting of Shareholders for Wednesday, October 19, 2016. In the event that you were a shareholder of record at the end of business on September 14, 2016, you are qualified for vote at the Special Meeting. Your intermediary support and vote is basic to accomplishing our objectives and assisting our prosperity.
As the president and CEO of EnteroMedics, as well as a kindred shareholder, I ask you to practice your entitlement to vote your shares. An update intermediary was sent out to unvoted shareholders a week ago. It would be ideal if you make incite move to vote your EnteroMedics offers, ideally by web or phone, by taking after the voting directions included with our intermediary materials.
In the event that you have not yet voted or lost your Proxy and need help with voting your shares, please contact The Proxy Advisory Group LLC, which is helping us, either by phone: 212-616-2180 or email: info@proxyadvisory.net.
We thank you for your intermediary support and anticipate offering our future victories to you.
Earnestly,
Dan W. Gladney
President and Chief Executive Officer
About EnteroMedics Inc.
EnteroMedics is a restorative gadget organization concentrated on the advancement and commercialization of its neuroscience based innovation to treat heftiness and metabolic illnesses. vBloc® Neurometabolic Therapy, conveyed by a pacemaker-like gadget called the vBloc® System, is intended to irregularly obstruct the vagus nerves utilizing high-recurrence, low-vitality, electrical motivations. EnteroMedics' vBloc® System has gotten U.S. Nourishment and Drug Administration endorsement and CE Mark.
Data about the vBloc® System and vBloc® Neurometabolic Therapy
You ought not have an embedded vBloc® System on the off chance that you have cirrhosis of the liver, hypertension in the veins of the liver, amplified veins in your throat or a critical hiatal hernia of the stomach; on the off chance that you require attractive reverberation imaging (MRI); in the event that you have a forever embedded, electrical medicinal gadget; or in the event that you require a diathermy method utilizing heat. The most widely recognized related antagonistic occasions that were experienced amid clinical investigation of the vBloc System included agony, acid reflux, sickness, trouble gulping, burping, wound redness or aggravation, and blockage.
Converse with your specialist about the full dangers and advantages of vBloc Therapy and vBloc System. For extra recommending data, please visit www.enteromedics.com.
On the off chance that you are keen on adapting more about vBloc Neurometabolic Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This official statement contains forward-looking proclamations about EnteroMedics Inc. Our genuine outcomes could vary tangibly from those talked about because of known and obscure dangers, instabilities and different elements including our constrained history of operations; our misfortunes since origin and for a long time to come; our restricted business deals involvement with our vBloc® System for the treatment of weight in the United States or in any outside market other than Australia and the European Community; our capacity to recover and afterward keep up consistence with the Nasdaq kept posting necessities; our capacity to popularize our vBloc® System; our reliance on outsiders to start and play out our clinical trials; the need to acquire administrative endorsement for any adjustments to our vBloc® System; doctor selection of our vBloc® System and vBloc® Neurometabolic Therapy; our capacity to get outsider coding, scope or installment levels; continuous administrative consistence; our reliance on outsider makers and providers; the fruitful improvement of our deals and showcasing capacities; our capacity to raise extra capital when required; universal commercialization and operation; our capacity to pull in and hold administration and other staff and to deal with our development successfully; potential item obligation claims; potential social insurance misrepresentation and manhandle claims; human services authoritative change; and our capacity to get and keep up licensed innovation security for our innovation and items. These and extra dangers and vulnerabilities are portrayed all the more completely in the Company's filings with the Securities and Exchange Commission, especially those variables distinguished as "hazard elements" in the yearly provide details regarding Form 10-K recorded March 28, 2016. We are giving this data as of the date of this official statement and don't attempt any commitment to upgrade any forward-looking proclamations contained in this report therefore of new data, future occasions or something else.
Logo - http://photos.prnewswire.com/prnh/20160502/362531LOGO
No comments:
Post a Comment
Note: only a member of this blog may post a comment.